Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
NKTR Nektar Therapeutics daily Stock Chart
NKTR [NASD]
Nektar Therapeutics
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.40 Insider Own0.70% Shs Outstand155.97M Perf Week-0.64%
Market Cap3.39B Forward P/E- EPS next Y-1.16 Insider Trans-43.35% Shs Float155.43M Perf Month20.57%
Income-209.20M PEG- EPS next Q0.23 Inst Own98.30% Short Float7.96% Perf Quarter19.77%
Sales133.10M P/S25.49 EPS this Y-79.50% Inst Trans3.04% Short Ratio11.23 Perf Half Y-0.37%
Book/sh0.02 P/B1087.50 EPS next Y-23.40% ROA-41.90% Target Price24.81 Perf Year14.53%
Cash/sh1.70 P/C12.78 EPS next 5Y-7.30% ROE- 52W Range11.41 - 24.88 Perf YTD77.26%
Dividend- P/FCF- EPS past 5Y1.50% ROI-33.80% 52W High-12.58% Beta1.45
Dividend %- Quick Ratio3.80 Sales past 5Y18.30% Gross Margin78.40% 52W Low90.62% ATR0.83
Employees468 Current Ratio4.00 Sales Q/Q5.50% Oper. Margin- RSI (14)55.36 Volatility3.89% 4.00%
OptionableYes Debt/Eq72.97 EPS Q/Q-8.10% Profit Margin- Rel Volume0.75 Prev Close22.60
ShortableYes LT Debt/Eq72.18 EarningsAug 08 AMC Payout- Avg Volume1.10M Price21.75
Recom1.70 SMA205.38% SMA505.45% SMA20023.69% Volume829,066 Change-3.76%
Aug-17-17Initiated Evercore ISI In-line $20
Aug-07-17Initiated H.C. Wainwright Buy $31
Mar-20-17Reiterated ROTH Capital Buy $23 → $31
Nov-08-16Initiated Aegis Capital Buy
Sep-30-16Resumed Brean Capital Buy
Jan-07-16Reiterated Piper Jaffray Overweight $16 → $20
Mar-18-15Reiterated ROTH Capital Buy $21 → $19
Mar-18-15Reiterated Brean Capital Buy $20 → $17
Sep-16-14Reiterated Brean Capital Buy $18 → $20
Jun-13-14Reiterated MKM Partners Neutral $13
Feb-27-14Downgrade MKM Partners Buy → Neutral
Sep-27-13Reiterated MKM Partners Buy $14 → $13
Sep-12-13Initiated Cowen Outperform $17
Aug-19-11Initiated MKM Partners Buy $12
Aug-08-11Reiterated Deutsche Bank Buy $14 → $11
May-17-11Initiated Boenning & Scattergood Outperform $15
Mar-02-11Reiterated Deutsche Bank Buy $16 → $14
Feb-15-11Downgrade ThinkEquity Buy → Hold $17 → $11
Dec-03-10Initiated ThinkEquity Buy $17
Jul-29-10Reiterated Deutsche Bank Buy $17 → $16
Sep-13-17 07:11PM  ETFs with exposure to Nektar Therapeutics : September 13, 2017 Capital Cube
11:32AM  Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate Zacks
Sep-12-17 09:00AM  Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab) PR Newswire
08:06AM  See what the IHS Markit Score report has to say about Nektar Therapeutics. Markit
Sep-11-17 02:06PM  Nektar Therapeutics :NKTR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Capital Cube
Sep-08-17 09:00AM  Surging Earnings Estimates Signal Good News for Nektar (NKTR) Zacks
Sep-06-17 06:00PM  Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek® PR Newswire
09:15AM  Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City PR Newswire
Sep-02-17 08:10AM  See what the IHS Markit Score report has to say about Nektar Therapeutics. Markit
Sep-01-17 10:03AM  Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : September 1, 2017 Capital Cube
08:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Ionis Pharmaceuticals Inc. ACCESSWIRE
Aug-30-17 09:00AM  Nektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek® PR Newswire
Aug-29-17 03:00AM  Nektar Therapeutics Earns Relative Strength Rating Upgrade; Hits Key Benchmark Investor's Business Daily
Aug-24-17 08:06AM  See what the IHS Markit Score report has to say about Nektar Therapeutics. Markit
Aug-16-17 09:41PM  Nektar Therapeutics Value Analysis (NASDAQ:NKTR) : August 17, 2017 Capital Cube
08:31AM  Are Options Traders Betting on a Big Move in Nektar (NKTR) Stock? Zacks
08:05AM  See what the IHS Markit Score report has to say about Nektar Therapeutics. Markit
08:00AM  Today's Research Reports on Stocks to Watch: Kite Pharma and Nektar Therapeutics ACCESSWIRE
Aug-15-17 08:05AM  See what the IHS Markit Score report has to say about Nektar Therapeutics. Markit
Aug-14-17 10:56AM  Will Nektar's (NKTR) Candidates Enhance Growth in 2017? Zacks +5.59%
08:05AM  See what the IHS Markit Score report has to say about Nektar Therapeutics. Markit
Aug-12-17 08:07AM  See what the IHS Markit Score report has to say about Nektar Therapeutics. Markit
06:21AM  Edited Transcript of NKTR earnings conference call or presentation 8-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-11-17 01:09PM  Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag Zacks
08:07AM  See what the IHS Markit Score report has to say about Nektar Therapeutics. Markit
Aug-08-17 06:48PM  Nektar reports 2Q loss Associated Press
04:10PM  Nektar Therapeutics Reports Financial Results for the Second Quarter of 2017 PR Newswire
02:10PM  Investor Network: Nektar Therapeutics to Host Earnings Call ACCESSWIRE
Aug-04-17 09:52AM  Nektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : August 4, 2017 Capital Cube
Aug-02-17 05:52PM  Nektar to Announce Financial Results for the Second Quarter of 2017 on Tuesday, August 8, 2017, After Close of U.S.-Based Financial Markets PR Newswire
Jul-27-17 08:46AM  Are Options Traders Betting on a Big Move in Nektar (NKTR) Stock? Zacks
Jul-26-17 07:00AM  Featured Company News - Eli Lilly and Nektar Announce Agreement to Co-Develop NKTR-358, the Self-Administered Injection for a Number of Autoimmune Disease Accesswire
Jul-25-17 07:19AM  Eli Lilly CEO: Strong quarter driven by new products CNBC Videos
Jul-24-17 04:29PM  Could This Small Biotech Break Out On A Tie-Up With Eli Lilly? Investor's Business Daily
11:33AM  Eli Lilly will co-develop autoimmune disease therapy under $150 million deal with Nektar MarketWatch
09:28AM  Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm TheStreet.com
08:15AM  Nektar Therapeutics surges 10% on $150 mln Eli Lilly deal MarketWatch
07:30AM  Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy PR Newswire
Jul-21-17 07:54AM  EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug Reuters
Jul-19-17 05:14PM  Nektar's NKTR-181 Positive in Human Abuse Potential Study Zacks
Jul-18-17 05:00PM  How This Biotech Could Dethrone Oxycodone In Treating Pain Investor's Business Daily
12:05PM  Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise TheStreet.com
08:00AM  Nektar Shares Boosted by Promising Results on Opioid Addiction Study TheStreet.com
08:00AM  Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain PR Newswire
Jul-12-17 08:10AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Catalyst Pharmaceuticals Inc. Accesswire
Jul-10-17 09:00AM  Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London PR Newswire
Jul-06-17 09:00AM  Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options Zacks
Jun-28-17 04:10PM  Is This Small Biotech Headed For $1 Billion Market Cap Or A Pitfall? Investor's Business Daily
Jun-22-17 08:13AM  Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : June 22, 2017 Capital Cube
Jun-16-17 02:26PM  Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why Zacks
Jun-09-17 01:48PM  ETFs with exposure to Nektar Therapeutics : June 9, 2017 Capital Cube
Jun-06-17 04:15PM  Nektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City PR Newswire
Jun-05-17 09:00AM  Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
Jun-02-17 08:41AM  Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : June 2, 2017 Capital Cube
May-31-17 12:01PM  Top Gainers in the Healthcare Sector: May 2226, 2017 Market Realist
May-30-17 11:12AM  Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017? Zacks -8.51%
May-22-17 09:00AM  New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds PR Newswire
May-19-17 04:26PM  Bristol-Incyte Match Beats Dow's Merck In Combination Trials Investor's Business Daily
May-18-17 08:39AM  Nektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : May 18, 2017 Capital Cube
08:00AM  Nektar Therapeutics Announces Data Presentations at ASCO 2017 PR Newswire
May-15-17 05:15PM  Edited Transcript of NKTR earnings conference call or presentation 9-May-17 9:00pm GMT Thomson Reuters StreetEvents
04:16PM  ETFs with exposure to Nektar Therapeutics : May 15, 2017 Capital Cube
04:15PM  Nektar to Webcast Presentation at UBS Global Healthcare Conference 2017 in New York PR Newswire
May-12-17 10:44AM  Nektar Therapeutics :NKTR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
May-11-17 09:46AM  Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1 Zacks
08:51AM  Edited Transcript of NKTR earnings conference call or presentation 9-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-10-17 05:18PM  The Not-So-Subtle Reason Behind Nektar Therapeutics' 10% Pop Motley Fool +8.15%
May-09-17 05:50PM  Nektar reports 1Q loss Associated Press
04:10PM  Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 PR Newswire
01:15PM  Investor Network: Nektar Therapeutics to Host Earnings Call Accesswire
May-08-17 06:03PM  Nektar Therapeutics Value Analysis (NASDAQ:NKTR) : May 8, 2017 Capital Cube
May-06-17 08:41AM  Why Nektar Therapeutics Shares Fell 19.2% in April Motley Fool
May-05-17 08:14AM  Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : May 5, 2017 Capital Cube
May-03-17 09:15AM  Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program PR Newswire
May-02-17 09:15AM  Nektar to Announce Financial Results for the First Quarter of 2017 on Tuesday, May 9, 2017, After Close of U.S.-Based Financial Markets PR Newswire
Apr-28-17 08:55AM  Biotech Surge: How To Survive In A Volatile Market Investor's Business Daily
Apr-20-17 09:10AM  Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting PR Newswire
Apr-19-17 10:44AM  How Nektar Therapeutics' Latest Drug Could Shake Up the Market for Pain Medicine Motley Fool
Apr-18-17 07:24AM  Can Drugmakers Cure the Opioid Crisis? Motley Fool
Apr-10-17 09:30AM  Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology Accesswire -8.01%
Apr-07-17 09:30AM  The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics Zacks
07:10AM  Nektar Therapeutics (NKTR) Up 57.2% Since Earnings Report: Can It Continue? Zacks
Apr-06-17 09:32AM  3 of the Best & Worst Performing Drug Stocks of Q1 Zacks
Apr-04-17 09:00AM  Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting PR Newswire
Apr-03-17 06:49PM  Cramer's lightning round: If we get two rate hikes, this stock's a good buy CNBC
Mar-30-17 04:42PM  3 Revolutionary Drugs for Chronic Pain Motley Fool
09:23AM  Western Digital, Nektar Therapeutics And Two More Stocks Breaking Out Forbes
Mar-29-17 02:10PM  Harry Boxers five technology and biotechnology stocks to watch MarketWatch
Mar-27-17 09:00AM  Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders PR Newswire
08:24AM  Trump is tapping Chris Christie to tackle the opioid epidemic here's a fix scientists hope he'll explore Business Insider
Mar-23-17 04:43PM  Could Nektar Therapeutics Be Worth More? Motley Fool
10:59AM  AstraZeneca Stock Rising in '17: What's Working in its Favor?
Mar-22-17 12:43PM  4 Biotech Stocks to Watch
Mar-21-17 12:09PM  Nektar Therapeutics (NKTR): Heres What Just Happened Insider Monkey
10:53AM  Nektar's Pain Drug Positive in Phase III Study; Shares Gain
09:30AM  Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News Accesswire
Mar-20-17 06:21PM  After-hours buzz: ESPR, NKTR, MMSI & more at CNBC +42.65%
04:41PM  Biotech Hits 11-Year High On Potential To Dethrone Oxycodone
01:41PM  Nektar Pharma Opioid Drug Shows Promise In Phase 3 at Investopedia
12:42PM  Nektar, AMD, Esperion, and More: Heres Why These Five Stocks Are Surging at Insider Monkey
Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The company's drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds license, manufacturing, and supply agreements with Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). It has a research collaboration agreement with Takeda Pharmaceutical Company Limited to explore the anti-cancer activity of NKTR-214; and a strategic collaboration with Eli Lilly and Company to develop and commercialize NKTR-358. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBIN HOWARD WPresident & CEOSep 06Option Exercise11.3483,333944,996235,837Sep 08 06:08 PM
ROBIN HOWARD WPresident & CEOSep 06Sale21.5483,3331,794,993152,504Sep 08 06:08 PM
ROBIN HOWARD WPresident & CEOAug 16Option Exercise11.3483,334945,008235,838Aug 18 07:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale19.322,64851,15950,838Aug 18 07:05 PM
Nicholson JohnSVP & Chief Operating OfficerAug 16Sale19.323,17761,380224,066Aug 18 07:04 PM
ROBIN HOWARD WPresident & CEOAug 16Sale19.2691,7141,766,081152,504Aug 18 07:05 PM
Hora ManinderSVP Pharma Dev & Mfg OpsAug 16Sale19.322,95657,11058,233Aug 18 07:03 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 16Sale19.323,17761,38063,414Aug 18 07:04 PM
Gergel Ivan P.SVP & Chief Medical OfficerAug 16Sale19.321,99738,58241,575Aug 18 07:02 PM
Doberstein Stephen KSVP & Chief Scientific OfficerAug 16Sale19.321,70132,86331,102Aug 18 07:01 PM
WHITFIELD ROY ADirectorAug 10Buy17.9535,000628,250133,000Aug 14 09:07 AM
Gergel Ivan P.SVP & Chief Medical OfficerJul 18Option Exercise11.0454,920606,31798,492Jul 20 05:08 PM
Gergel Ivan P.SVP & Chief Medical OfficerJul 18Sale21.1054,9201,158,81243,572Jul 20 05:08 PM
Lingnau LutzDirectorJul 14Option Exercise14.2630,000427,80053,450Jul 18 08:02 PM
Lingnau LutzDirectorJul 14Sale20.7630,000622,80023,450Jul 18 08:02 PM
Gergel Ivan P.SVP & Chief Medical OfficerJul 12Option Exercise11.0436,691405,06980,263Jul 13 08:01 PM
Gergel Ivan P.SVP & Chief Medical OfficerJul 12Sale21.0936,691773,81343,572Jul 13 08:01 PM
Gergel Ivan P.SVP & Chief Medical OfficerJul 11Option Exercise11.048,38992,61551,961Jul 13 08:01 PM
Gergel Ivan P.SVP & Chief Medical OfficerJul 11Sale21.048,389176,50543,572Jul 13 08:01 PM
Krivulka Joseph JDirectorJun 26Option Exercise8.3715,000125,55073,000Jun 28 06:05 PM
Nicholson JohnSVP & Chief Operating OfficerJun 07Option Exercise6.34150,000951,000328,943Jun 09 06:02 PM
Nicholson JohnSVP & Chief Operating OfficerJun 07Sale19.24101,7001,956,708227,243Jun 09 06:02 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale19.552,65151,82752,986May 18 08:50 PM
ROBIN HOWARD WPresident & CEOMay 16Sale19.558,388163,985160,884May 18 08:50 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale19.553,14661,504178,943May 18 08:49 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale19.553,17962,14966,091May 18 08:48 PM
Gergel Ivan P.SVP & Chief Medical OfficerMay 16Sale19.551,45028,34843,572May 18 08:46 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale19.552,95957,84860,689May 18 08:47 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale19.551,70133,25532,803May 18 08:45 PM
CHESS ROBERTDirectorMay 15Option Exercise8.375,00041,850276,623May 17 06:02 PM
CHESS ROBERTDirectorMay 15Sale19.795,00098,950271,623May 17 06:02 PM
CHESS ROBERTDirectorApr 17Option Exercise8.375,00041,850276,623Apr 19 07:30 PM
CHESS ROBERTDirectorApr 17Sale18.725,00093,600271,623Apr 19 07:30 PM
Lingnau LutzDirectorApr 07Sale20.057,000140,35023,450Apr 11 06:04 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 05Option Exercise9.53100,000953,000134,504Apr 07 06:07 PM
KUEBLER CHRISTOPHER ADirectorApr 05Option Exercise8.3715,000125,55050,500Apr 07 06:01 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Option Exercise13.70180,0002,466,000243,648Apr 07 06:05 PM
KUEBLER CHRISTOPHER ADirectorApr 05Sale21.8815,000328,20035,500Apr 07 06:01 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Sale21.70180,0003,906,00063,648Apr 07 06:05 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 05Sale21.70100,0002,170,00034,504Apr 07 06:07 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMar 20Option Exercise9.96112,5001,120,875168,137Mar 22 06:04 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMar 20Sale19.69112,5002,215,12555,637Mar 22 06:04 PM
WHITFIELD ROY ADirectorMar 15Option Exercise8.3714,000117,18098,000Mar 17 06:02 PM
CHESS ROBERTDirectorMar 14Option Exercise8.375,00041,850276,623Mar 16 06:02 PM
CHESS ROBERTDirectorMar 14Sale15.415,00077,050271,623Mar 16 06:02 PM
Labrucherie Gil MSVP & Chief Financial OfficerMar 03Option Exercise8.5732,494278,51294,270Mar 03 07:04 PM
Labrucherie Gil MSVP & Chief Financial OfficerMar 03Sale15.2132,494494,23469,270Mar 03 07:04 PM
Labrucherie Gil MSVP & Chief Financial OfficerMar 02Option Exercise6.34167,5061,061,988236,776Mar 03 07:04 PM
Labrucherie Gil MSVP & Chief Financial OfficerMar 02Sale15.15167,5062,537,71669,270Mar 03 07:04 PM
Lingnau LutzDirectorFeb 21Option Exercise5.1430,000154,20060,450Feb 23 06:32 PM
Lingnau LutzDirectorFeb 21Sale13.0830,000392,40030,450Feb 23 06:32 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 16Sale13.141,96525,82055,637Feb 17 08:06 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 16Sale13.143,23742,534182,089Feb 17 08:05 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale13.148,636113,477169,272Feb 17 08:06 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 16Sale13.142,35930,99769,270Feb 17 08:04 PM
Gergel Ivan P.SVP & Chief Medical OfficerFeb 16Sale13.141,45719,14545,022Feb 17 08:03 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 16Sale13.142,19528,84263,648Feb 17 08:04 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 16Sale13.141,26116,57034,504Feb 17 08:02 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 10Option Exercise4.6545,000209,250185,326Feb 10 08:11 PM
ROBIN HOWARD WPresident & CEOFeb 08Option Exercise4.6587,500406,875265,408Feb 10 08:10 PM
ROBIN HOWARD WPresident & CEOFeb 08Sale13.0487,5001,141,000177,908Feb 10 08:10 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 03Option Exercise4.658,50539,548148,831Feb 06 05:20 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 03Sale12.488,505106,142140,326Feb 06 05:20 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 02Option Exercise4.6566,495309,202206,821Feb 06 05:20 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 02Sale12.3866,495823,208140,326Feb 06 05:20 PM
ROBIN HOWARD WPresident & CEOJan 17Option Exercise4.6587,500406,875265,408Jan 19 08:01 PM
ROBIN HOWARD WPresident & CEOJan 17Sale12.3587,5001,080,625177,908Jan 19 08:01 PM
ROBIN HOWARD WPresident & CEODec 07Option Exercise4.6587,500406,875210,408Dec 09 06:03 PM
ROBIN HOWARD WPresident & CEODec 07Sale12.2487,5001,071,000122,908Dec 09 06:03 PM
ROBIN HOWARD WPresident & CEONov 17Option Exercise4.6587,500406,875210,408Nov 18 06:12 PM
ROBIN HOWARD WPresident & CEONov 17Sale13.8787,5001,213,625122,908Nov 18 06:12 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale13.961,98627,72542,102Nov 18 06:12 PM
ROBIN HOWARD WPresident & CEONov 16Sale13.965,95883,174122,908Nov 18 06:12 PM
Nicholson JohnSVP & Chief Operating OfficerNov 16Sale13.961,65423,090120,326Nov 18 06:11 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 16Sale13.961,65423,09050,343Nov 18 06:09 PM
Labrucherie Gil MSVP & Chief Financial OfficerNov 16Sale13.961,65423,09051,129Nov 18 06:10 PM
Gergel Ivan P.SVP & Chief Medical OfficerNov 16Sale13.9684811,83826,479Nov 18 06:08 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 16Sale13.966709,35318,265Nov 18 06:07 PM
GREER R SCOTTDirectorOct 24Buy13.5015,000202,500121,333Oct 25 05:00 PM
ROBIN HOWARD WPresident & CEOOct 04Option Exercise4.6587,500406,875216,366Oct 06 05:07 PM
ROBIN HOWARD WPresident & CEOOct 04Sale17.0687,5001,492,750128,866Oct 06 05:07 PM
WHITFIELD ROY ADirectorSep 23Option Exercise5.2146,000239,82084,000Sep 27 05:09 PM
open in yahoo | open in reuters | open in google